首页> 外国专利> DERIVATIVES OF PYRIMIDINODIONE, PYRIMIDINOTRIONE, TRIAZINODIONE AND TETRAHYDROQUINAZOLINODIONE AND METHOD OF OBTAINING THEM

DERIVATIVES OF PYRIMIDINODIONE, PYRIMIDINOTRIONE, TRIAZINODIONE AND TETRAHYDROQUINAZOLINODIONE AND METHOD OF OBTAINING THEM

机译:嘧啶二酮,嘧啶三酮,三嗪二酮和四氢喹唑啉二酮的衍生物及其获得方法

摘要

The present invention relates to novel alpha 1-adrenoceptor antagonists of the formula I CHEM in which: R1 is acetylamino, amino, cyano, trifluoroacetylamino, halo, hydro, hydroxy, nitro, methylsulfonylamino, 2-propynyloxy, a group selected from (C1-6)alkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl(C1-4)alkyl, (C1-6)alkyloxy, (C3-6)cycloalkyloxy, (C3-6)cycloalkyl(C1-4)alkyloxy and (C1-4)alkylthio (which group is optionally further substituted with one to three halo atoms) or a group selected from aryl, aryl(C1-4)alkyl, heteroaryl, heteroaryl(C1-4)alkyl, aryloxy, aryl(C1-4)alkyloxy, heteroaryloxy and heteroaryl(C1-4)alkyloxy (which aryl and heteroaryl are optionally further substituted with one to two radicals independently selected from halo and cyano); R2 is cyano, halo, hydro, hydroxy or a group selected from (C1-6)alkyl and (C1-6)alkyloxy (which group is optionally further substituted with one to three halogen atoms); R3 and R4 are both hydro or methyl or together are ethylene; and R5 is a group selected from Formulae (a), (b), (c) and (d): CHEM in which: X is C(O), CH2 or CH(OH); Y is CH2 or CH(OH); Z is N or C(R9), wherein R9 is hydro, (C1-6)alkyl or hydroxy; R6 is hydro, a group selected from (C1-6)alkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl(C1-4)alkyl (which group is optionally further substituted with one to three halo atoms) or a group selected from aryl, heteroaryl, aryl(C1-4)alkyl and heteroaryl(C1-4)alkyl (which aryl and heteroaryl are optionally further substituted with one to three radicals selected from halo, cyano, (C1-6)alkyloxy, (C1-6)alkyl and aryl); R7 is (C1-6)alkanoyl, carbamoyl, cyano, di(C1-6)alkylamino, halo, hydro, hydroxy, hydroxyiminomethyl, (C1-6)alkylsulfonyl, (C1-6)alkylthio, a group selected from (C1-6)alkyl, (C3-6)cycloalkyl, (C1-6)alkyloxy and (C1-6)alkyloxy(C1-4)alkyl (which group is optionally further substituted with one to three radicals selected from halo, hydroxy or (C1-6)alkyloxy) or a group selected from aryl, heteroaryl, aryl(C1-4)alkyl and heteroaryl(C1-4)alkyl (which aryl and heteroaryl are optionally further substituted with one to three radicals selected from halo, cyano, (C1-6)alkyloxy, (C1-6)alkyl and aryl) or R7 and R9 together are tetramethylene; and each R8 is independently hydro, hydroxy, methyl or ethyl; and the pharmaceutically acceptable salts and N-oxides thereof.
机译:本发明涉及式I 的新型α1-肾上腺素受体拮抗剂,其中:R 1为乙酰氨基,氨基,氰基,三氟乙酰氨基,卤素,氢,羟基,硝基,甲基磺酰氨基,2-丙炔基氧基,选自(C1-6)烷基,(C3-6)环烷基,(C3-6)环烷基(C1-4)烷基,(C1-6)烷氧基,(C3-6)环烷氧基,(C3-6)环烷基( C 1-4)烷氧基和(C 1-4)烷硫基(其基团还任选被一个至三个卤素原子取代)或选自芳基,芳基(C 1-4)烷基,杂芳基,杂芳基(C 1-4)烷基的基团;芳氧基,芳基(C1-4)烷氧基,杂芳氧基和杂芳基(C1-4)烷氧基(其中芳基和杂芳基任选进一步被1-2个独立地选自卤素和氰基的基团取代); R 2为氰基,卤素,氢,羟基或选自(C 1-6)烷基和(C 1-6)烷氧基的基团(该基团任选地进一步被1-3个卤素原子取代); R 3和R 4均为氢或甲基,或一起为乙烯; R 5为选自式(a),(b),(c)和(d)的基团:<化学式>其中X为C(O),CH 2或CH(OH); Y为CH 2或CH(OH); Z为N或C(R 9),其中R 9为氢,(C 1-6)烷基或羟基; R 6是氢,选自(C 1-6)烷基,(C 3-6)环烷基,(C 3-6)环烷基(C 1-4)烷基的基团(该基团任选地进一步被1-3个卤原子取代) )或选自芳基,杂芳基,芳基(C1-4)烷基和杂芳基(C1-4)烷基的基团(其中芳基和杂芳基任选地进一步被选自卤素,氰基,(C1-6)的1-3个基团取代烷氧基,(C 1-6)烷基和芳基); R 7为选自以下的基团:(C1-6)烷酰基,氨基甲酰基,氰基,二(C1-6)烷基氨基,卤素,氢,羟基,羟基亚氨基甲基,(C1-6)烷基磺酰基,(C1-6)烷硫基。 (C 1-6)烷基,(C 3-6)环烷基,(C 1-6)烷氧基和(C 1-6)烷氧基(C 1-4)烷基(该基团任选地进一步被选自卤素,羟基的1-3个基团取代) (C1-6)烷氧基)或选自芳基,杂芳基,芳基(C1-4)烷基和杂芳基(C1-4)烷基的基团(其中芳基和杂芳基任选地进一步被选自卤素的1-3个基团取代,氰基,(C 1-6)烷氧基,(C 1-6)烷基和芳基)或R 7和R 9一起为四亚甲基;每个R 8独立地为氢,羟基,甲基或乙基;及其药学上可接受的盐和N-氧化物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号